Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
Heba A. Hassan , Mahitab M. Nageeb , Heba Osama Mohammed , Walaa Samy , Amal Fawzy , Rofaida Afifi , Noha A.T. Abbas
{"title":"Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis","authors":"Heba A. Hassan ,&nbsp;Mahitab M. Nageeb ,&nbsp;Heba Osama Mohammed ,&nbsp;Walaa Samy ,&nbsp;Amal Fawzy ,&nbsp;Rofaida Afifi ,&nbsp;Noha A.T. Abbas","doi":"10.1016/j.taap.2024.116991","DOIUrl":null,"url":null,"abstract":"<div><p>Liver fibrosis is considered an epidemic health problem due to different insults that lead to death. Dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is one of the newer anti-diabetic drugs used to manage type 2 diabetes mellitus (T2DM). DAPA exerted beneficial effects in many human and rat models due to its antioxidant, anti-inflammatory and antifibrotic activities.</p></div><div><h3>Aim</h3><p>Due to previously reported capabilities related to DAPA, we designed this study to clarify the beneficial role of DAPA in liver fibrosis triggered by common bile duct ligation (CBL) in male rats.</p></div><div><h3>Methods</h3><p>For 14 or 28 days after CBL procedures, DAPA was administered to the rats orally at a dose of 10 mg/kg once daily. The effects of DAPA were evaluated by assaying liver enzymes, hepatic oxidant/antioxidant parameters, serum levels of tumor necrotic factor alpha (TNF-α), and AMP-activated protein kinase (AMPK). In addition, we measured the hepatic expression of fibrosis regulator-related genes along with evaluating liver histological changes.</p></div><div><h3>Key findings</h3><p>DAPA successfully decreased hepatic enzymes and malondialdehyde levels, increased superoxide dismutase activity, elevated catalase levels, decreased serum levels of TNF-α, elevated serum levels of AMPK, decreased liver hydroxyproline content, upregulated Sirt1/PGC1α/FoxO1 liver gene expressions, down-regulated fibronectin-1 (Fn-1), collagen-1 genes in liver tissues, and improved the damaged liver tissues. Deteriorated biochemical parameters and histological liver insults associated with CBL were more pronounced after 28 days, but DAPA administration for 14 and 28 days showed significant improvement in most parameters and reflected positively in the histological structures of the liver.</p></div><div><h3>Significance</h3><p>The significance of this study lies in the observation that DAPA mitigated CBL-induced liver fibrosis in rats, most likely due to its antioxidant, anti-inflammatory, and antifibrotic effects. These results suggest that DAPA's beneficial impact on liver fibrosis might be attributed to its interaction with the Sirt1/AMPK/PGC1α/FoxO1 pathway, indicating a potential mechanistic action for future exploration.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041008X24001893","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Liver fibrosis is considered an epidemic health problem due to different insults that lead to death. Dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is one of the newer anti-diabetic drugs used to manage type 2 diabetes mellitus (T2DM). DAPA exerted beneficial effects in many human and rat models due to its antioxidant, anti-inflammatory and antifibrotic activities.

Aim

Due to previously reported capabilities related to DAPA, we designed this study to clarify the beneficial role of DAPA in liver fibrosis triggered by common bile duct ligation (CBL) in male rats.

Methods

For 14 or 28 days after CBL procedures, DAPA was administered to the rats orally at a dose of 10 mg/kg once daily. The effects of DAPA were evaluated by assaying liver enzymes, hepatic oxidant/antioxidant parameters, serum levels of tumor necrotic factor alpha (TNF-α), and AMP-activated protein kinase (AMPK). In addition, we measured the hepatic expression of fibrosis regulator-related genes along with evaluating liver histological changes.

Key findings

DAPA successfully decreased hepatic enzymes and malondialdehyde levels, increased superoxide dismutase activity, elevated catalase levels, decreased serum levels of TNF-α, elevated serum levels of AMPK, decreased liver hydroxyproline content, upregulated Sirt1/PGC1α/FoxO1 liver gene expressions, down-regulated fibronectin-1 (Fn-1), collagen-1 genes in liver tissues, and improved the damaged liver tissues. Deteriorated biochemical parameters and histological liver insults associated with CBL were more pronounced after 28 days, but DAPA administration for 14 and 28 days showed significant improvement in most parameters and reflected positively in the histological structures of the liver.

Significance

The significance of this study lies in the observation that DAPA mitigated CBL-induced liver fibrosis in rats, most likely due to its antioxidant, anti-inflammatory, and antifibrotic effects. These results suggest that DAPA's beneficial impact on liver fibrosis might be attributed to its interaction with the Sirt1/AMPK/PGC1α/FoxO1 pathway, indicating a potential mechanistic action for future exploration.

达帕格列酮抑制胆总管结扎诱导的大鼠肝纤维化与肝脏Sirt1/AMPK/PGC1α/FoxO1轴的增强有关
肝纤维化被认为是一种流行性健康问题,因为不同的损伤会导致死亡。达帕格列净(DAPA)是一种钠-葡萄糖共转运体-2(SGLT2)抑制剂,是用于控制2型糖尿病(T2DM)的新型抗糖尿病药物之一。由于之前报道了 DAPA 的相关功能,我们设计了这项研究,以明确 DAPA 在雄性大鼠胆总管结扎(CBL)引发的肝纤维化中的有益作用。方法在胆总管结扎手术后的 14 或 28 天内,以 10 mg/kg 的剂量给大鼠口服 DAPA,每天一次。通过检测肝酶、肝脏氧化剂/抗氧化剂参数、血清肿瘤坏死因子α(TNF-α)和AMP激活蛋白激酶(AMPK)水平来评估DAPA的作用。此外,我们还测量了肝纤维化调节相关基因的表达,并评估了肝组织学变化。主要发现DAPA成功地降低了肝酶和丙二醛的水平,提高了超氧化物歧化酶的活性,升高了过氧化氢酶的水平,降低了血清中TNF-α的水平,升高了血清中AMPK的水平,降低了肝脏中羟脯氨酸的含量,上调了肝脏中Sirt1/PGC1α/FoxO1基因的表达,下调了肝组织中纤维连接蛋白-1(Fn-1)和胶原蛋白-1基因的表达,改善了受损的肝组织。本研究的意义在于观察到 DAPA 可减轻 CBL 诱导的大鼠肝纤维化,这很可能是由于它具有抗氧化、抗炎和抗纤维化作用。这些结果表明,DAPA 对肝纤维化的有利影响可能归因于其与 Sirt1/AMPK/PGC1α/FoxO1 通路的相互作用,这表明其潜在的作用机理有待未来的探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信